| Literature DB >> 35015085 |
Niki Marjerrison1, Jarle Jakobsen, Tom K Grimsrud, Johnni Hansen, Jan Ivar Martinsen, Karl-Christian Nordby, Marit B Veierød, Kristina Kjærheim.
Abstract
OBJECTIVES: Firefighters are exposed to a variety of known and suspected carcinogens through their work. However, the association with cancer risk has limited evidence. We examined cancer incidence among firefighters in the newly established Norwegian Fire Departments Cohort restricted to sites with established associations with carcinogens encountered during firefighting. This included sites within the respiratory, urinary, and lympho-hematopoietic systems, and the skin and all sites combined.Entities:
Mesh:
Year: 2022 PMID: 35015085 PMCID: PMC9523464 DOI: 10.5271/sjweh.4009
Source DB: PubMed Journal: Scand J Work Environ Health ISSN: 0355-3140 Impact factor: 5.492
Figure 1Flowchart of the study cohort of male firefighters in the Norwegian Fire Departments Cohort, 1950–2018.
Characteristics of the study sample, male firefighters in the Norwegian Fire Departments Cohort (N=3881). Follow-up from 1 January 1960 to 31 December 2018.
| Characteristics | N (SD) | % |
|---|---|---|
| Person-years at risk | 108 358 | |
| Mean years of follow-up | 27.9 (16.1) | |
| Status on December 31, 2018 | ||
| Emigrated | 27 | 0.7 |
| Dead | 1105 | 28.5 |
| Alive | 2749 | 70.8 |
| Year of birth | ||
| <1950 | 1542 | 39.7 |
| 1950–1969 | 1147 | 29.6 |
| ≥1970 | 1192 | 30.7 |
| Age at first employment (years) | ||
| <30 | 2928 | 75.4 |
| 30–49 | 920 | 23.7 |
| ≥50 | 33 | 0.9 |
| Year of first employment | ||
| <1950 | 655 | 16.9 |
| 1950–1969 | 574 | 14.8 |
| 1970–1989 | 1144 | 29.5 |
| ≥1990 | 1508 | 38.8 |
| Duration of employment (years) | ||
| <10 | 1006 | 25.9 |
| 10–19 | 683 | 17.6 |
| 20–29 | 716 | 18.5 |
| 30–39 | 1362 | 35.1 |
| ≥40 | 114 | 2.9 |
Observed number of cases and standardized incidence ratios (SIR) with 95% confidence intervals (CI) for selected cancer sites and all cancers combined among male firefighters (N=3881) in the Norwegian Fire Departments Cohort. Follow-up from 1 January 1960 to 31 December 2018. [ICD=International Classification of Diseases].
| Cancer site | ICD-10 | Observed | SIR | 95% CI |
|---|---|---|---|---|
| Larynx | C32 | 12 | 1.77 | 0.91–3.08 |
| Lung | C33-C34 | 81 | 0.98 | 0.78–1.22 |
| Cutaneous melanoma | C43 | 47 | 1.30 | 0.95–1.73 |
| Non-melanoma skin [ | C44 | 35 | 0.99 | 0.69–1.37 |
| Mesothelioma | C45 | 7 | 2.46 | 0.99–5.06 |
| Kidney [ | C64 | 29 | 1.28 | 0.86–1.84 |
| Urinary tract [ | C65-C68 | 69 | 1.25 | 0.97–1.58 |
| Hodgkin lymphoma | C81 | 2 | 0.53 | 0.06–1.91 |
| Non-Hodgkin lymphoma | C82-C86, C96 | 26 | 1.17 | 0.76–1.71 |
| Multiple myeloma | C90 | 9 | 0.79 | 0.36–1.51 |
| Leukaemia | C91-C95 | 14 | 0.83 | 0.46–1.40 |
| Exposure-associated sites [ | 331 | 1.10 | 0.98–1.22 | |
| All cancers | C00-C96 | 845 | 1.15 | 1.07–1.23 |
Excluding basal cell carcinoma.
Excluding renal pelvis.
Including bladder and renal pelvis.
Includes the following sites: C32, C33-C34, C43, C44, C45, C64, C65-C68, C81, C82-C86, C90, C91-C95, C96
Stratification of observed number of cases and standardized incidence ratios (SIR) with 95% confidence intervals (CI) for selected cancer sites and all cancers combined among male firefighters (N=3881) in the Norwegian Fire Departments Cohort. Follow-up from 1 January 1960 to 31 December 2018. [ICD= International Classification of Diseases; Obs=observed; pyr=person-years].
| Cancer site | Year of first employment | |||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| <1950 (N=655) | 1950–1969 (N=574) | ≥1970 (N=2652) | ||||||
|
|
|
| ||||||
| Obs | SIR (95% CI) | Obs | SIR (95% CI) | Obs | SIR (95% CI) | |||
| Larynx | 6 | 2.34 (0.86–5.09) | 5 | 2.02 (0.65–4.71) | 1 | 0.57 (0.01–3.18) | ||
| Lung | 40 | 1.37 (0.98–1.87) | 28 | 0.87 (0.58–1.26) | 13 | 0.61 (0.33–1.04) | ||
| Cutaneous melanoma | 8 | 1.38 (0.59–2.71) | 19 | 1.53 (0.92–2.38) | 20 | 1.11 (0.68–1.72) | ||
| Non-melanoma skin [ | 9 | 0.72 (0.33–1.37) | 17 | 1.10 (0.64–1.76) | 9 | 1.20 (0.55–2.28) | ||
| Mesothelioma | 3 | 3.74 (0.77–10.9) | 2 | 1.52 (0.18–5.49) | 2 | 2.74 (0.33–9.90) | ||
| Kidney [ | 10 | 1.61 (0.77–2.96) | 9 | 1.24 (0.57–2.35) | 10 | 1.09 (0.52–2.01) | ||
| Urinary tract [ | 35 | 1.71 (1.19–2.38) | 22 | 1.04 (0.65–1.58) | 12 | 0.88 (0.45–1.54) | ||
| Hodgkin lymphoma | 0 | 0.00 (0.00–3.75) | 2 | 2.29 (0.28–8.28) | 0 | 0.00 (0.00–1.42) | ||
| Non-Hodgkin lymphoma | 6 | 1.14 (0.42–2.47) | 9 | 1.20 (0.55–2.27) | 11 | 1.17 (0.58–2.09) | ||
| Multiple myeloma | 5 | 1.21 (0.39–2.82) | 1 | 0.25 (0.01–1.40) | 3 | 0.93 (0.19–2.71) | ||
| Leukaemia | 5 | 0.91 (0.29–2.11) | 4 | 0.72 (0.20–1.84) | 5 | 0.88 (0.29–2.05) | ||
| Exposure-associated sites [ | 127 | 1.36 (1.14–1.62) | 118 | 1.07 (0.89–1.28) | 86 | 0.93 (0.74–1.15) | ||
| All cancers | 304 | 1.29 (1.15–1.44) | 284 | 1.08 (0.96–1.22) | 257 | 1.08 (0.95–1.22) | ||
|
| ||||||||
| Cancer site | Time since first employment | |||||||
|
| ||||||||
| <20 years (52 093 pyr) | 20–39 years (41 034 pyr) | ≥40 years (15 230 pyr) | ||||||
|
|
|
| ||||||
| Obs | SIR (95% CI) | Obs | SIR (95% CI) | Obs | SIR (95% CI) | |||
|
| ||||||||
| Larynx | 0 | 0.00 (0.00–7.04) | 2 | 0.59 (0.07–2.14) | 10 | 3.33 (1.60–6.13) | ||
| Lung | 4 | 1.07 (0.29–2.74) | 22 | 0.64 (0.40–0.98) | 55 | 1.23 (0.93–1.60) | ||
| Cutaneous melanoma | 9 | 1.33 (0.61–2.53) | 21 | 1.36 (0.84–2.08) | 17 | 1.21 (0.70–1.94) | ||
| Non-melanoma skin [ | 3 | 2.14 (0.44–6.26) | 8 | 0.97 (0.42–1.96) | 24 | 0.93 (0.59–1.38) | ||
| Mesothelioma | 0 | 0.00 (0.00–30.4) | 1 | 0.98 (0.02–5.46) | 6 | 3.47 (1.27–7.55) | ||
| Kidney [ | 1 | 0.47 (0.01–2.64) | 15 | 1.41 (0.79–2.32) | 13 | 1.32 (0.70–2.26) | ||
| Urinary tract [ | 3 | 1.13 (0.23–3.30) | 17 | 0.86 (0.50–1.38) | 49 | 1.49 (1.10–1.97) | ||
| Hodgkin lymphoma | 0 | 0.00 (0.00–1.70) | 0 | 0.00 (0.00–2.19) | 2 | 3.05 (0.37–11.0) | ||
| Non-Hodgkin lymphoma | 4 | 1.30 (0.35–3.32) | 14 | 1.50 (0.82–2.52) | 8 | 0.81 (0.35–1.61) | ||
| Multiple myeloma | 0 | 0.00 (0.00–4.31) | 4 | 0.88 (0.24–2.26) | 5 | 0.82 (0.27–1.91) | ||
| Leukaemia | 1 | 0.48 (0.01–2.70) | 6 | 0.92 (0.34–1.99) | 7 | 0.86 (0.34–1.77) | ||
| Exposure-associated sites [ | 25 | 1.01 (0.65–1.49) | 110 | 0.96 (0.79–1.16) | 196 | 1.25 (1.08–1.44) | ||
| All cancers | 66 | 1.09 (0.84–1.39) | 314 | 1.12 (1.00–1.25) | 465 | 1.18 (1.08–1.29) | ||
|
| ||||||||
| Cancer site | Duration of employment | |||||||
|
| ||||||||
| <10 years (33 405 pyr) | 10–19 years (26 539 pyr) | 20–29 years (24 930 pyr) | ≥30 years (23 483 pyr) | |||||
|
|
|
|
| |||||
| Obs | SIR (95% CI) | Obs | SIR (95% CI) | Obs | SIR (95% CI) | Obs | SIR (95% CI) | |
|
| ||||||||
| Larynx | 0 | 0.00 (0.00–5.55) | 2 | 2.70 (0.33–9.75) | 1 | 0.51 (0.01–2.85) | 9 | 2.53 (1.16–4.80) |
| Lung | 4 | 0.62 (0.17–1.59) | 7 | 0.86 (0.34–1.76) | 18 | 0.81 (0.48–1.29) | 52 | 1.14 (0.85–1.49) |
| Cutaneous melanoma | 10 | 1.84 (0.88–3.38) | 5 | 0.85 (0.27–1.98) | 13 | 1.38 (0.73–2.35) | 19 | 1.23 (0.74–1.92) |
| Non-melanoma skin [ | 3 | 1.02 (0.21–2.98) | 5 | 1.56 (0.51–3.63) | 7 | 0.83 (0.34–1.72) | 20 | 0.96 (0.58–1.48) |
| Mesothelioma | 1 | 4.21 (0.11–23.4) | 0 | 0.00 (0.00–11.4) | 1 | 1.38 (0.03–7.66) | 5 | 3.09 (1.00–7.20) |
| Kidney [ | 3 | 1.32 (0.27–3.85) | 3 | 1.07 (0.22–3.14) | 6 | 0.95 (0.35–2.06) | 17 | 1.51 (0.88–2.42) |
| Urinary tract [ | 8 | 1.82 (0.79–3.60) | 3 | 0.55 (0.11–1.60) | 22 | 1.54 (0.97–2.34) | 36 | 1.16 (0.81–1.60) |
| Hodgkin lymphoma | 0 | 0.00 (0.00–2.46) | 0 | 0.00 (0.00–3.63) | 0 | 0.00 (0.00–3.64) | 2 | 2.17 (0.26–7.85) |
| Non-Hodgkin lymphoma | 2 | 0.72 (0.09–2.61) | 4 | 1.28 (0.35–3.27) | 10 | 1.68 (0.81–3.10) | 10 | 0.96 (0.46–1.77) |
| Multiple myeloma | 1 | 1.07 (0.03–5.97) | 0 | 0.00 (0.00–2.47) | 4 | 1.32 (0.36–3.39) | 4 | 0.65 (0.18–1.66) |
| Leukaemia | 2 | 1.02 (0.12–3.70) | 2 | 0.94 (0.11–3.38 | 0 | 0.00 (0.00–0.69) | 10 | 1.20 (0.57–2.20) |
| Exposure-associated sites [ | 34 | 1.17 (0.81–1.63) | 31 | 0.91 (0.62–1.30) | 82 | 1.06 (0.84–1.32) | 184 | 1.18 (1.02–1.37) |
| All cancers | 74 | 1.01 (0.79–1.27) | 87 | 1.06 (0.85–1.31) | 217 | 1.15 (1.00–1.32) | 467 | 1.19 (1.09–1.30) |
Excluding basal cell carcinoma.
Excluding renal pelvis.
Including bladder and renal pelvis.
Includes the following sites: C32, C33-C34, C43, C44, C45, C64, C65-C68, C81, C82-C86, C90, C91-C95, C96